OnKure Therapeutics, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
OnKure Therapeutics reported Q2 2026 cash, cash equivalents, and marketable securities of $176.4M (as of June 30, 2026), expected to fund operations into 2029. The company is advancing two next-generation PI3K-alpha pan-mutant selective inhibitor candidates—OKI-355 (vascular anomalies) and OKI-345 (breast cancer)—with IND submissions planned for 1H 2027. Q2 2026 net loss was $15.3M ($0.31 per share) on R&D expenses of $12.6M and G&A expenses of $4.3M; weighted average shares outstanding increased to 49.9M from 13.5M year-over-year, reflecting a strategic transformation earlier in 2026.
Why this rating
Strong cash position ($176M) extends runway on a $28M market cap company—highly positive. However, filing is routine quarterly disclosure with no new partnerships, regulatory approvals, or clinical data. Candidate selection (March 2026) and strategy announced previously. No material change to business trajectory reported.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.